Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 1
2008 5
2009 3
2010 1
2011 1
2012 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, McKeegan EM, Fox GB. Luo Y, et al. Among authors: hradil vp. Cancer Chemother Pharmacol. 2012 Apr;69(4):911-21. doi: 10.1007/s00280-011-1740-7. Epub 2011 Nov 12. Cancer Chemother Pharmacol. 2012. PMID: 22080168
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.
Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, Hsieh GC, Honore P, Frost JM, Dart MJ, Meyer MD, Yao BB, Cox BF, Fox GB. Chin CL, et al. Among authors: hradil vp. Br J Pharmacol. 2008 Jan;153(2):367-79. doi: 10.1038/sj.bjp.0707506. Epub 2007 Oct 29. Br J Pharmacol. 2008. PMID: 17965748 Free PMC article.
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y. Liu X, et al. Among authors: hradil vp. Mol Cancer Res. 2008 Oct;6(10):1621-9. doi: 10.1158/1541-7786.MCR-08-0240. Mol Cancer Res. 2008. PMID: 18922977 Free article.
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD. Yao BB, et al. Among authors: hradil vp. J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17. J Pharmacol Exp Ther. 2009. PMID: 18931146
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page